The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

AZN ASTRAZENECA PLC ORD SHS $0.25




 Page 1 of 6

| 1 | 2 | 3 | 4 | 5 | 6 | Next

Time/Date Code Headline Source Impact
07:00 18-Sep-2019 AZN AstraZeneca amends collaboration with Ironwood RNS +2.37% Up
08:38 09-Sep-2019 AZN Imfinzi is first immunotherapy to show both RNS -6.15% Down
07:11 04-Sep-2019 AZN Tagrisso approved in China as a 1st-line treatment RNS -3.32% Down
15:00 02-Sep-2019 AZN Total Voting Rights RNS +0.86% Up
07:05 02-Sep-2019 AZN Brilinta reduced the risk of cardiovascular events RNS +0.86% Up
07:00 02-Sep-2019 AZN Detailed results from Phase III DAPA-HF trial RNS +0.86% Up
07:00 29-Aug-2019 AZN Anifrolumab Phase III trial meets primary endpoint RNS +1.67% Up
07:05 28-Aug-2019 AZN Fasenra granted US Orphan Drug Designation for RNS +0.82% Up
07:00 28-Aug-2019 AZN Breztri Aerosphere Phase III ETHOS trial met RNS +0.82% Up
07:00 22-Aug-2019 AZN Roxadustat approved in China for the treatment of RNS -0.05% Down
07:00 22-Aug-2019 AZN AstraZeneca agrees to buy US FDA Priority Review RNS -0.05% Down
07:00 21-Aug-2019 AZN Update on the Phase III NEPTUNE trial RNS +0.84% Up
07:00 20-Aug-2019 AZN Farxiga met primary endpoint in landmark Phase III RNS +0.74% Up
07:00 19-Aug-2019 AZN Directorate Change RNS +0.47% Up
07:00 14-Aug-2019 AZN Lynparza Phase III PAOLA-1 trial met primary endpo RNS -0.18% Down
07:00 14-Aug-2019 AZN Calquence granted US Breakthrough Therapy Designat RNS -0.18% Down
09:28 09-Aug-2019 AZN Amendment: Tagrisso significantly improves overall RNS +2.12% Up
07:00 07-Aug-2019 AZN Lynparza Phase III PROfound trial in HRR* RNS +1.95% Up
07:00 05-Aug-2019 AZN Forxiga label updated in the EU in type-2 diabetes RNS +0.18% Up
15:00 01-Aug-2019 AZN Total Voting Rights RNS +1.75% Up

 Page 1 of 6

| 1 | 2 | 3 | 4 | 5 | 6 | Next



Price changes are calculated on the basis of the following formula: [ avg(x) - avg(y)] / avg(y) where:
x = instrument's 7 closing prices after the news has been released
y = instrument's latest 7 closing prices before the news was released, including the day of the release of the news

Please note that the news releases are only one of the multiple factors that could have had an impact on the change in the security’s price over the time period analysed by the News Analysis tool. Where data are insufficient the graph does not show any price change and the table below the graph displays a blank “ - “ next to the line indicating the RNS issue.




Company Information
Company website http://www.astrazeneca....
Company address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, United Kingdom
FTSE ICB sector Pharmaceuticals, Biotechnology and Marijuana Producers
FTSE ICB subsector Pharmaceuticals
Company market cap, £m* 93,497.89
Admission date 01 Jun 1993
*The company market capitalization reflects the London listed element of Ordinary and Preference shares only and is approximate. Data provided by FTSE Russell.


Security Information
FTSE index FTSE 100,FTSE 350,FTSE 350 Low Yield,FTSE 350 (ex IT),FTSE All-Share,FTSE All-Share (ex IT),FTSE Eurotop 100 Index,FTSE Eurotop 300,FTSE techMARK All-Share
Market Main Market
Market identifier code (MIC) XLON
Trading service SETS
Trading segment SET1
Listing category Premium Equity Commercial Companies
Country of share register GB
ISIN GB0009895292
SEDOL 0989529
Exchange market size 300
Security market cap, £m 93,497.89
*The market capitalisation of the security reflects data from previous trading day.


ASTRAZENECA share news analysis (AZN)